Table 1 Characteristics of patients.
From: Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
2022 ELN | All patients nā=ā624 | Favorable nā=ā205 | Intermediate nā=ā295 | Adverse nā=ā124 | Ā | ||||
|---|---|---|---|---|---|---|---|---|---|
N | % | N (%) | % | n | % | n | % | p-value | |
Age, year | |||||||||
Ā Median (range) | 51 | (18ā84) | 47.5 | (18ā83) | 50 | (18ā83) | 57 | (18ā84) | Ā |
Ā āā„ā65Ā years | 89 | 14.3% | 25 | 12.2% | 38 | 12.9% | 26 | 21.0% | 0.056 |
Sex | |||||||||
Ā Male | 324 | 51.9% | 102 | 49.8% | 137 | 46.4% | 85 | 68.5% | ā<ā0.001 |
Disease type | |||||||||
Ā De novo AML | 577 | 92.5% | 194 | 94.6% | 275 | 93.2% | 108 | 87.1% | 0.054 |
Ā Secondary AML | 34 | 5.4% | 6 | 2.9% | 15 | 5.1% | 13 | 10.5% | Ā |
Ā Treatment-related AML | 13 | 2.1% | 5 | 2.4% | 5 | 1.7% | 3 | 2.4% | Ā |
Genetic abnormalities | |||||||||
Ā t (8;21) | 62 | 9.9% | 62 | 30.2% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā inv(16) or t(16;16) | 27 | 4.3% | 27 | 13.2% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā t(9;11) | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā t(6;9) | 1 | 0.0% | 0 | 0.0% | 0 | 0.0% | 1 | 0.8% | Ā |
Ā t(v;11q23.3) | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā t(9;22) | 5 | 0.1% | 0 | 0.0% | 0 | 0.0% | 5 | 4.0% | Ā |
Ā t(8;16) | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā inv(3) or t(3;3) | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā t(3q26.2;v) | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā āĀ 5, del(5q); -7;-17/abn(17p) | 7 | 1.1% | 0 | 0.0% | 0 | 0.0% | 7 | 5.6% | Ā |
Ā Complex karyotype, monosomal karyotype | 17 | 2.7% | 0 | 0.0% | 0 | 0.0% | 17 | 13.7% | Ā |
Ā Mutated NPM1 without FLT3-ITD | 81 | 13.0% | 81 | 39.5% | 0 | 0.0% | 0 | 0.0% | Ā |
Ā Mutated NPM1 with FLT3-ITD | 67 | 10.7% | 0 | 0.0% | 61 | 20.7% | 6 | 4.8% | Ā |
Ā Wild-type NPM1 with FLT3-ITD | 48 | 7.7% | 6 | 2.9% | 48 | 16.3% | 10 | 8.1% | Ā |
Ā bZIP in-frame mutated CEBPĪ± | 37 | 5.9% | 36 | 17.6% | 0 | 0.0% | 1 | 0.8% | Ā |
Ā Mutated ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, ZRSR2 | 94 | 15.1% | 16 | 6.8% | 0 | 0.0% | 78 | 62.9% | Ā |
Ā Mutated TP53 | 19 | 3.0% | 2 | 0.9% | 0 | 0.0% | 17 | 13.7% | Ā |
2017 ELN | |||||||||
Ā Favorable | 218 | 34.9% | 184 | 89.8% | 31 | 10.5% | 3 | 2.4% | ā<ā0.001 |
Ā Intermediate | 298 | 47.8% | 21 | 10.2% | 231 | 78.3% | 46 | 37.1% | Ā |
Ā Adverse | 108 | 17.3% | 0 | 0.00% | 33 | 11.2% | 75 | 60.5% | Ā |
CR-achieved | |||||||||
Ā Yes | 523 | 83.8% | 189 | 92.2% | 252 | 85.4% | 82 | 66.1% | ā<ā0.001 |
Allogeneic HCT (nā=ā523) | |||||||||
Ā Yes | 235 | 44.9% | 81 | 42.9% | 112 | 44.4% | 42 | 51.2% | 0.592 |
